Exchange: NASDAQ·Updated 07:30 PM EDT

GILD News

News
all
press releases
If You Invested $100 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 2.42% on an annualized basis producing an average annual return of 11.56%. Currently, Gilead Sciences has a market capitalization ofread more...
Benzinga
More News
Here's Why You Should Add NRIX Stock to Your Portfolio Now
Nurix is developing bexobrutideg in CLL, while Roche's $2.3B deal and new studies support its potential in cancer, immunology and neurology.
Zacks
Will The Recent Pipeline Progress Boost BMY's Portfolio Expansion?
Bristol Myers Squibb's positive arlo-cel data in heavily pretreated multiple myeloma could strengthen its cell therapy pipeline.
Zacks
Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key Insights
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $146.64, denoting a -2.88% move from the preceding trading day.
Zacks
Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines
Gilead Sciences, Inc. (Nasdaq: GILD) today celebrated the opening of its 182,000-square-foot Research Center at its Foster City headquarters, expanding capabilities in oncology, inflammation and research data science to advance medicines for some of the worlds most challenging diseases. The new...
Business Wire
Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play?
Key PointsGilead is best known for its dominant HIV franchise...
Nasdaq News: Markets
Why Is Gilead (GILD) Up 13.6% Since Last Earnings Report?
Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Can LLY's Merida Deal Boost Its M&A Push to Diversify Beyond GLP-1s?
Eli Lilly's 10th deal of 2026 expands its immunology pipeline, underscoring an aggressive push to build growth drivers beyond its blockbuster cardiometabolic franchise.
Zacks
Top Research Reports for Toyota Motor, CrowdStrike & Welltower
Toyota Motor's hybrid growth and expanded value-chain businesses support demand, but higher costs, China weakness and leverage temper prospects.
Zacks
Can Bixlenvo Unlock New Growth for Gilead's HIV Business?
GILD's FDA approval of Bixlenvo expands its HIV portfolio with a first-of-its-kind single-tablet option for underserved patients.
Zacks

Advertisement|Remove ads.